Central Institute Of Mental Health, Mannheim

This study is testing whether adding cannabidiol (CBD), a non-psychoactive compound from cannabis, to standard antipsychotic medication helps people with schizophrenia stay on treatment longer and improves their symptoms. It will involve 180 people who have been diagnosed within …